First Tracks Biotherapeutics $TRAX Shares Sold by Moody Aldrich Partners LLC

Moody Aldrich Partners LLC cut its holdings in First Tracks Biotherapeutics (NASDAQ:TRAX) by 36.0% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 34,748 shares of the company’s stock after selling 19,568 shares during the period. Moody Aldrich Partners LLC’s holdings in First Tracks Biotherapeutics were worth $1,231,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of TRAX. State Street Corp bought a new stake in shares of First Tracks Biotherapeutics during the 2nd quarter valued at about $30,439,000. Opaleye Management Inc. acquired a new stake in First Tracks Biotherapeutics during the second quarter worth about $1,308,000. Wellington Management Group LLP acquired a new stake in First Tracks Biotherapeutics during the second quarter worth about $1,156,000. Tidal Investments LLC bought a new position in First Tracks Biotherapeutics in the second quarter worth about $622,000. Finally, Corient Private Wealth LP bought a new position in First Tracks Biotherapeutics in the second quarter worth about $610,000.

Insider Buying and Selling at First Tracks Biotherapeutics

In related news, Director J. Ware sold 39,265 shares of First Tracks Biotherapeutics stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $44.78, for a total value of $1,758,286.70. Following the sale, the director directly owned 15,660 shares in the company, valued at $701,254.80. This trade represents a 71.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

First Tracks Biotherapeutics Trading Down 1.1%

TRAX stock opened at $45.22 on Friday. First Tracks Biotherapeutics has a 1 year low of $14.72 and a 1 year high of $49.91. The company has a fifty day moving average of $38.86.

First Tracks Biotherapeutics (NASDAQ:TRAX) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.21). As a group, analysts predict that First Tracks Biotherapeutics will post -4.31 EPS for the current year.

Analysts Set New Price Targets

TRAX has been the subject of a number of research reports. Piper Sandler lifted their target price on First Tracks Biotherapeutics from $54.00 to $95.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Leerink Partners upped their target price on First Tracks Biotherapeutics from $70.00 to $90.00 and gave the company an “outperform” rating in a report on Friday, October 16th. Wedbush increased their price target on First Tracks Biotherapeutics from $60.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, August 13th. Barclays increased their price target on First Tracks Biotherapeutics from $48.00 to $65.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Finally, Wolfe Research began coverage on First Tracks Biotherapeutics in a report on Tuesday, August 18th. They issued an “outperform” rating and a $83.00 price target on the stock. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $71.33.

First Tracks Biotherapeutics Profile

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.